

12/11/01
JC951 U.S. PTO

Please type a plus sign (+) inside this box

+

PTO/SB/05 (11-00)

Approved for use through 10/31/2002 OMB 0651-0032 U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	690068.405C3
	First Inventor	Nicholas Ling
	Title	METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS USING PEPTIDE ANALOGUES OF HUMAN MYELIN BASIC PROTEIN
	Express Mail Label No.	EV020612829US

J1021 U.S. PTO
10/015540

12/11/01

1. Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i>	7. CD-ROM or CD-R in duplicate, large table or Computer Program <i>(Appendix)</i>
2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i>
3. <input checked="" type="checkbox"/> Specification [Total Pages <u>30</u>] <i>(preferred arrangement set forth below)</i>	a. Computer Readable Form (CRF)
- Descriptive title of the Invention	b. Specification Sequence Listing on:
- Cross Reference to Related Applications	i. CD-ROM or CD-R (2 copies); or
- Statement Regarding Fed sponsored R & D	ii. paper
- Reference to sequence listing, a table, or a computer program listing appendix	c. Statements verifying identity of above copies
- Background of the Invention	
- Brief Summary of the Invention	
- Brief Description of the Drawings <i>(if filed)</i>	
- Detailed Description	
- Claim(s)	
- Abstract of the Disclosure	
4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <u>4</u>]	
5. Oath or Declaration [Total Sheets <u>3</u>]	
a. Newly executed (original or copy)	
b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63 (d)) <i>(for a continuation/divisional with Box 18 completed)</i>	
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)	
6. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	

ACCOMPANYING APPLICATION PARTS	
9.	Assignment Papers (cover sheet & document(s))
10.	37 CFR 3.73(b) Statement Power of <i>(when there is an assignee)</i> Attorney
11.	English Translation Document <i>(if applicable)</i>
12.	Information Disclosure Copies of IDS
	Statement (IDS)/PTO-1449 Citations
13.	Preliminary Amendment
14. <input checked="" type="checkbox"/>	Return Receipt Postcard (MPEP 503) <i>Should be specifically itemized</i>
15.	Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>
16.	Request and Certification under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17.	Other: _____


18. If a CONTINUING APPLICATION OR APPLICATION CLAIMING FOREIGN PRIORITY, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) ☒ Claims priority from U.S. application
No. 08/342,408, filed 11/18/94

Prior application information Examiner Michael Borin, Ph.D. Group Art Unit 1631

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Correspondence address below		or:	<input checked="" type="checkbox"/> Customer Number or Bar Code Label
Firm Name			 00500
Address			
City, State, Zip			

Signature

By signing this Statement, the filer is certifying that the information provided is true and correct to the best of the filer's knowledge. Any false or misleading information provided may result in the application being rejected or the filer being subject to disciplinary action. This form is required to be completed and filed with the application. It should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. (USPTO) (USPTO) (USPTO)